|
| Status |
Public on Oct 27, 2015 |
| Title |
control shRNA - 3 |
| Sample type |
RNA |
| |
|
| Source name |
HuCCT1 cholangiocarcinoma cell line
|
| Organism |
Homo sapiens |
| Characteristics |
vector: control shRNA
treatment: Doxicycline
|
| Treatment protocol |
To induce expression of shRNA cells were treated with 100ng/ml DOX (Sigma) 3 days before seeding for an experiment
|
| Growth protocol |
HuCCT1 cells were maintained in RPMI-1640 supplemented with 10% (v/v) Tetracycline-free fetal bovine serum, 2mM L-Glutamine, 1mM sodium pyruvate and 0.1mM MEM non-essential amino acids
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated from cells using the RNeasy Plus mini kit according to the manufacturer’s instructions (Qiagen). RNA quality was assessed with the RNA 6000 Nano Kit (Agilent). 500 µg RNA of each sample were reverse-transcribed using the high capacity cDNA reverse transcription kit (Applied Biosystems)
|
| Label |
biotin
|
| Label protocol |
Nugen Ovation RNA Amplification System+ WB + FL cDNA Biotin Module V2 - Affymetrix Hybridization control kit (including B2)
|
| |
|
| Hybridization protocol |
standard Affymetrix protocol
|
| Scan protocol |
standard Affymetrix protocol
|
| Data processing |
Data was analyzed using a custom Bioconductor script based on the affycoretools package
|
| |
|
| Submission date |
Sep 25, 2014 |
| Last update date |
Oct 27, 2015 |
| Contact name |
Yann Abraham |
| Organization name |
Novartis Pharma AG
|
| Department |
NIBR/DMP
|
| Street address |
Postfach
|
| City |
Basel |
| ZIP/Postal code |
CH-4002 |
| Country |
Switzerland |
| |
|
| Platform ID |
GPL570 |
| Series (2) |
| GSE61765 |
Effect of YAP overexpression on HuCCT1 cholangiocarcinoma cell line transcriptome (shRNA targeting YAP) |
| GSE61767 |
Effect of YAP overexpression on HuCCT1 cholangiocarcinoma cell line transcriptome |
|
